Max Hodak, the cofounder of Neuralink, has set his sights on a new company that has piqued his interest. While he claims there’s no bad blood between him and his former company, his recent investments suggest otherwise.

Hodak recently raised $47 million for a brain interface venture called Science Corp and has also personally invested in Synchron, a competitor of Neuralink. In a blog post, Hodak expressed his enthusiasm for supporting Synchron and helping them succeed in any way he can.

Synchron stands out from Neuralink by accessing the brain through blood vessels instead of implanting a chip via the skull. The company has already started human trials and achieved remarkable results, such as enabling a man with ALS to tweet using their technology.

On the other hand, Neuralink has yet to reach human trials, with Elon Musk announcing plans to start implanting chips in 2022 without a specific timeline. Hodak’s involvement with Synchron adds to the challenges Neuralink has been facing, casting doubts on the company’s future.

As the competition between Neuralink and its rivals heats up, the question remains: which company will lead the way in brain-computer interface technology? Hodak’s strategic investments could play a significant role in shaping the future of this innovative industry.

For a deeper dive into the rivalry between Neuralink and its competitors, check out the article from Insider. And if you’re curious about the inner workings of Neuralink, former employees have some fascinating stories to share about working under Elon Musk’s leadership.

The race to revolutionize brain-computer interfaces is gaining momentum, and Hodak’s involvement in these groundbreaking advancements is certainly something to watch closely.